Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China

BACKGROUND: Lung cancer is imposing significant pressure on the national health insurance system worldwide, especially under the COVID-19 pandemic. However, the cost-effectiveness of all available first-line treatments for patients with advanced epidermal growth factor receptor (EGFR) mutated non-sm...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Haijing, Wang, Chunping, Chen, Chen, Han, Sheng, Zhao, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241581/
https://www.ncbi.nlm.nih.gov/pubmed/35785198
http://dx.doi.org/10.3389/fonc.2022.819674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241581/
https://www.ncbi.nlm.nih.gov/pubmed/35785198
http://dx.doi.org/10.3389/fonc.2022.819674

Ejemplares similares